

## Title (en)

TISSUE TARGETED ANTIGENIC ACTIVATION OF THE IMMUNE RESPONSE TO TREAT CANCERS

## Title (de)

AUF GEWEBE GEZIELTE ANTIGEN-AKTIVIERUNG DER IMMUNANTWORT ZUR BEHANDLUNG VON KREBS

## Title (fr)

ACTIVATION ANTIGÉNIQUE DE LA RÉPONSE IMMUNITAIRE CIBLÉE SUR DES TISSUS POUR TRAITER DES CANCERS

## Publication

**EP 2094293 A4 20100929 (EN)**

## Application

**EP 07816065 A 20071025**

## Priority

- CA 2007001915 W 20071025
- US 55397206 A 20061027
- CA 2571805 A 20061220

## Abstract (en)

[origin: EP3338797A1] An anti-inflammatory and an immunogenic composition for use in providing a synergistic effect for the treatment of a cancer situated in a specific organ or tissue in a human patient, by a method comprising: selecting at least one microbial pathogen that is pathogenic in the specific organ or tissue of the patient within which the cancer is situated; producing an antigenic composition comprising antigenic determinants that together are specific for the microbial pathogen; and, formulating the antigenic composition for administration as an immunogenic composition capable of eliciting an immune reaction to treat the cancer in the patient, and administering the anti-inflammatory and the immunogenic composition to the patient.

## IPC 8 full level

**A61K 39/00** (2006.01); **A61K 35/76** (2006.01); **A61K 39/02** (2006.01); **A61K 39/12** (2006.01); **A61P 35/00** (2006.01); **A61P 35/04** (2006.01); **A61P 37/04** (2006.01); **C07K 14/005** (2006.01); **A61K 35/74** (2015.01)

## CPC (source: CN EP US)

**A61K 35/74** (2013.01 - CN); **A61K 35/742** (2013.01 - CN); **A61K 35/744** (2013.01 - CN); **A61K 39/0011** (2013.01 - CN EP US); **A61K 39/0266** (2013.01 - CN EP); **A61K 39/085** (2013.01 - CN EP); **A61K 39/092** (2013.01 - CN EP); **A61K 39/095** (2013.01 - CN EP); **A61K 39/102** (2013.01 - CN EP); **A61K 39/12** (2013.01 - EP); **A61P 35/00** (2018.01 - EP); **A61K 35/74** (2013.01 - EP); **A61K 35/76** (2013.01 - EP); **A61K 2039/521** (2013.01 - CN EP); **A61K 2039/5252** (2013.01 - EP); **A61K 2039/542** (2013.01 - EP); **A61K 2039/57** (2013.01 - EP); **A61K 2039/585** (2013.01 - CN EP); **A61K 2039/70** (2013.01 - CN EP); **Y02A 50/30** (2018.01 - EP)

## C-Set (source: CN)

1. **A61K 39/092 + A61K 2300/00**
2. **A61K 39/095 + A61K 2300/00**
3. **A61K 39/102 + A61K 2300/00**
4. **A61K 39/085 + A61K 2300/00**
5. **A61K 39/0266 + A61K 2300/00**
6. **A61K 35/74 + A61K 2300/00**
7. **A61K 35/742 + A61K 2300/00**
8. **A61K 35/744 + A61K 2300/00**

## Citation (search report)

- [X] WO 0223994 A1 20020328 - MAYO FOUNDATION [US], et al
- [X] US 6348586 B1 20020219 - CHANG YUAN [US], et al
- [X] BUSSE E ET AL: "INFLUENCE OF CYCLIC AMP LEVEL AND INTERFERON LEVEL IN THE LYMPHOCYTES AND CHANGE IN THE RATE OF TAKING ROOT OF THE TUMOR OF A TRANSPLANTABLE MELANOMA OF THE SYRIAN HAMSTER BY TREATMENT WITH BCG MEASLES VACCINE AS WELL AS L DOPA AND AMANTADINE", RADIOBIOLOGIA RADIOTHERAPIA, vol. 21, no. 3, 1980, pages 292 - 301, XP009137692, ISSN: 0033-8184
- [X] PFALBERG A ET AL: "Inverse association between melanoma and previous vaccinations against tuberculosis and smallpox: results of the FEBIM study", JOURNAL OF INVESTIGATIVE DERMATOLOGY, NATURE PUBLISHING GROUP, GB LNKD- DOI:10.1046/J.1523-1747.2002.00643.X, vol. 119, no. 3, 1 September 2002 (2002-09-01), pages 570 - 575, XP008109657, ISSN: 0022-202X
- [X] JAMES MACLEAN ET AL: "Vaccination strategies for the prevention of cervical cancer", EXPERT REVIEW OF ANTICANCER THERAPY, FUTURE DRUGS, LONDON, GB LNKD- DOI:10.1586/14737140.5.1.97, vol. 5, no. 1, 1 January 2005 (2005-01-01), pages 97 - 107, XP008110291, ISSN: 1473-7140

## Citation (examination)

- ATSUKO FUJIHARA ET AL: "Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, vol. 57, no. 1, 30 June 2007 (2007-06-30), pages 73 - 84, XP019561055, ISSN: 1432-0851, DOI: 10.1007/S00262-007-0351-Y
- M. KUROOKA ET AL: "Inactivated Sendai Virus Particles Eradicate Tumors by Inducing Immune Responses through Blocking Regulatory T Cells", CANCER RESEARCH, vol. 67, no. 1, 1 January 2007 (2007-01-01), pages 227 - 236, XP055121699, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-06-1615
- See also references of WO 2008049231A1

## Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

## DOCDB simple family (publication)

**EP 3338797 A1 20180627**; AU 2007308721 A1 20080502; AU 2007308721 B2 20130620; CA 2571805 A1 20080427; CA 2571805 C 20180501; CA 2997459 A1 20080427; CA 2997459 C 20200922; CN 101636176 A 20100127; CN 107412759 A 20171201; EP 2094293 A1 20090902; EP 2094293 A4 20100929

## DOCDB simple family (application)

**EP 18156810 A 20071025**; AU 2007308721 A 20071025; CA 2571805 A 20061220; CA 2997459 A 20061220; CN 200780048022 A 20071025; CN 201710281964 A 20071025; EP 07816065 A 20071025